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development of brain metastases (BM) is one 
of the major challenges for patients with stage 
III and IV breast cancer. In a recent study, brain 
metastases-free survival differed significantly 
between breast cancer subtypes and was 
shortest in patients with triple receptor-
negative cancer. Central nervous system 
(CNS) metastases account for the majority 
of malignant brain tumors, and may appear 
either within the brain parenchyma or along 
the leptomeninges. Breast cancer is the second 
most common cause of CNS metastases, and is 
the solid tumor most commonly associated 
with leptomeningeal metastases. 1,2
On the basis of case series from the 1960s 
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 Abstract 
 
 Objective: Breast cancer is the second most common cause of brain 
metastasis (BM) among all of the solid cancers, with metastases occurring 
in 10%–16% of patients and in as many as 30% of autopsy studies. Breast 
cancer-related BM usually has a poor prognosis and survival rate in the 
absence of any treatment within 2 months. Survival after BM is related 
to the subtype of the primary tumor. Human epidermal growth factor-2 
(HER-2)-positive patients have a significantly better prognosis compared 
with other subtypes. The prognosis for the majority of patients with 
BM remains poor, despite local and systemic therapies, with a median 
survival of around 10 months.
 Methods: This case is interesting because our patient is very young, 
diagnosed with BM before breast cancer was identified, bit still surviving 
12 months after her BM diagnosis. A 19-year old woman presented with 
seizures, vomit and headaches.
 Results: A cranial CT-scan showed an intracranial mass. The intracranial 
tumor was removed, and yielded a histopathological result of metastatic 
adenocarcinoma. Further examination found a lump in her right breast. 
She was diagnosed with intracranial metastatic stage 4 luminal B Her 2(+) 
breast cancer. She was referred for WBRT, a mastectomy, chemotherapy 
with docetaxel cyclophosphamide 4 cycles, followed by 12 cycles of 
trastuzumab, and continued treatment with tamoxifen and goserelin. The 
last PET-Scan showed no residual disease.
 Conclusion: Breast cancer as the primary tumor should be considered in 
women with a metastatic brain tumor. With appropriate treatment, even 
stage IV luminal B breast cancer with BM can still have a long life with 
good quality.  
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Advanced Breast Cancer (ABC) comprises 
both locally advanced breast cancer (LABC) 
and metastatic breast cancer (MBC). Although 
treatable, MBC remains an incurable disease 
with a median overall survival (OS) of three 
years and a 5-years survival of only 25%. The 
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and 1970s, the incidence of clinically evident 
brain metastases among women with stage 
IV breast cancer is estimated to be 10% 
to 16%. These figures underestimate the 
true incidence, given that brain metastases 
are found in 30% of patients at autopsy. 
Parenchymal brain metastases typically 
follow a vascular distribution, consistent 
with a mechanism of hematogenous spread. 
Supratentorial lesions are more common 
than infratentorial lesions, and there is a 
predilection for vascular border zones and the 
gray and white matter junction. In contrast, 
leptomeningeal metastases arise via multiple 
pathways, including hematogenous spread, 
direct extension, and infiltration from vertebral 
metastases via Batson’s plexus. Involvement 
of the leptomeninges is less common clinically 
than parenchymal metastases, and is found in 
5% to16% of patients at autopsy.3,4
Young age appears to be a risk factor for the 
development of CNS metastases. For example, 
in an autopsy review of 1,044 patients with 
breast cancer, the median age of patients with 
CNS metastases was about 5 years younger 
than that of patients without CNS metastases. 
Several groups have also found an association 
between the hormone receptor status and 
the incidence of CNS relapse, although these 
studies generally have been small in scale. In 
one study of 217 women with primary breast 
cancer, estrogen receptor (ER)–negative 
breast cancers were more likely to metastasize 
to the brain (10% vs 4% clinical incidence). In 
an autopsy study of 25 patients, ER-negative 
tumors were also more likely to metastasize 
to the leptomeninges. Whether this observed 
association relates to the inherent biology of 
ER-negative tumors, the ability of hormonal 
therapy to penetrate the CNS (thereby 
providing a relative risk reduction for 
ER-positive tumors), and/or the inverse 
relationship between the hormone receptor 
and the HER2 status is unclear on the basis of 
the available evidence. The association of CNS 
metastases with the human epidermal growth 
factor receptor 2 (Her2) overexpression 
merits special mention. An amplification of 
HER2 is present in 25% to 30% of human 
breast cancers and correlates with diminished 
disease-free and overall survival. Among 319 
women with primary breast cancer, HER2 
overexpression was the strongest predictor 
of the site of the first relapse in a multivariate 
model, with a 4.3% vs 0.4% incidence of brain 
metastases.3,5 
The most common presenting symptom of 
parenchymal brain metastases is a headache, 
occurring in 24% to 48% of patients. Other 
common manifestations include mental status 
changes and cognitive disturbances, which are 
present in 24% to 34% of patients.6 
This case is interesting because our patient 
is very young, presenting with BM before her 
breast cancer diagnosis, but still surviving 21 
months after her BM diagnosis.
Case 
In April 2018, a 19-year-old woman came 
to our hospital with seizures, blurred eyes, 
headaches and vomiting. She consulted a 
neurosurgeon and underwent a brain CT-
scan on the 3rd of April, 2018. The CT-scan 
revealed a multilobulated tumor mass with 
cystic components on the edges including 
right ventricular posterior pericocalus / right 
parietal lobe and the medial right occipital 
lobe (size ± 4.54x3.88x4.27 cm) accompanied 
by extensive perifocal edema vitalizing the 
posterior right lateral and ventricular III 
ventricles and a mild midline shift to the left 
as much as ± 0.76 cm pushing the midbrain to 
anterior inferior, suggestive of a high-grade 
glioma. There were also multiple lacunae / 
ischemic degeneration lesions in the white 
frontal lobe white matter. There was no acute 
infarction, bleeding, vascular malformations 
or intracranial space occupying lesions. A 
craniotomy with a biopsy was performed. 
Histopathology showed metastatic of papillary 
adenocarcinoma with difficulty in ascertaining 
its origin. The patient was then treated with 
whole brain radiotherapy (WBRT). While 
undergoing WBRT, the patient was referred to 
medical oncology for further evaluation of the 
primary tumor. A palpable 4-cm hard, painless 
mass was found in the lower right quadrant 
of her right breast. She had had a lump in her 
right breast since November 2017 but it had 
not been evaluated. She had had menarche 
at the age of 11 and her grandmother had 
suffered from breast cancer. A positron 
emission tomography (PET) scan was carried 
out and showed an irregular mass in the lower 
right quadrant of the medial right breast with 
central necrosis accompanied by metabolic 
activity at the periphery, highly suggestive of 
malignancy. A hypermetabolic lobulated mass 
in the right parietooccipital surrounded by 
the peripheral area of  the edema and pressing 
the posterior to the right lateral ventricle is 
consistent for a metastasis. No hypermetabolic 
lesions were seen in the lymph nodes or other 
organs suggestive of malignancies / other 
metastases. A reevaluation of the intracranial 
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biopsy tissue showed malignant tumor 
forming papillary structures section of the 
anaplastic cells with rounded and pleomorphic 
nuclei, hyperchromatic, a moderate amount 
of cytoplasm, the mitotic count was twenty 
two per ten high power field (22/10 hpf). 
The differential diagnosis were metastatic 
adenocarcinoma and anaplastic ependymoma.
She underwent an incisional biopsy on her 
breast lump. Breast histopathology showed a 
malignant breast tumor invading stroma and 
fat. The tumor was composed of anaplastic 
epithelial cells with marked pleiomorphic 
nuclei (score 3), coarse chromatin and 
prominent nuclei, the mitotic count was 
twenty five per ten hpf (score 3), arranged in 
solid clusters (tubular structures <10%, score 
3), with necrosis in the central part of the 
tumor. There were ductal carcinoma insitu foci 
in peripheral parts of the tumor, mostly solid 
types with a few comedo types, high grade. 
Lymphovascular and perineural invasion were 
not found. Immunohistochemistry staining 
showed estrogen receptor (ER) positive of 80%, 
weak to moderately stained, progesterone 
receptor (PR) positive of 5% weak stained, 
Her-2 +3 for the herceptest score and a 
Ki67 expression of 75% (An invasive breast 
carcinoma of no special type pathological 
grade III luminal B, Her2 positive). The patient 
underwent a right mastectomy which showed 
metastasis in 1 of 5 axillary lymph nodes. She 
underwent 4 cycles of chemotherapy with 
docetaxel and cyclophosphamide and 12 cycles 
with trastuzumab. In September 2018, the 
patient continued therapy with tamoxifen. In 
October 2018, a PET-scan showed no residual 
disease. The patient continued treatment 
with tamoxifen and goserelin and has since 
remained in remission.
Discussion
Generally, patients having breast cancer brain 
metastases (BCBM) is associated with a poor 
prognosis. The outcome for these patients 
remains poor even after chemotherapy 
and radiotherapy. Most BCBM patients are 
characterized by rapid growing, hormone 
receptor negative and/or Her-2 positive 
tumors concurrent with visceral metastases.7 
Breast cancer is divided into three distinct 
diseases with heterogeneous expression of 
estrogen receptor/progesteron receptor (ER/
PgR) and Her2 status. Luminal type cancers, 
which are ER/PgR positive without a Her2-
positive status, tend to be the most favorable 
for long-term survival. Whereas, the triple 
negative subtype (basal-like) and Her2-
positive tumors are the most sensitive to 
chemotherapy, but have the poorest prognosis. 
Of women diagnosed with advanced breast 
cancer, 10% to 16% develop central nervous 
system (CNS) metastases. Several risk factors 
have been associated with the development 
of CNS lesions in patients with MBC, including 
being of a younger age (<50 year), having more 
than two metastatic sites at MBC diagnosis, 
and being Her2-positive. Patients with Her2-
positive MBC tumors are 2 to 4 times more 
likely to develop CNS tumors than patients who 
are Her2-negative. The proportion of patients 
with brain metastases in triple-negative, Her2-
positive status and luminal subtypes was 28%, 
53% and 19%, respectively. This indicates 
that triple-negative and Her2-positive breast 
cancer have a special predisposition to 
metastasize to the brain.8 In one study, Mauer C 
et al., found that the median OS for BC without 
BM was 46.7 months (IQR 23.0–145.6 months) 
and for BCBM patients 20.8 months (IQR 5.36-
not reached). Patients without CNS symptoms 
at the time of their BM diagnosis had a better 
OS than patients with clinical signs related to 
their BM (HR 0.49, 95% CI 0.25 to 0.94).9 
CNS involvement typically occurs late in 
the course of metastatic breast cancer. In 
most cases, the involvement of the lungs, 
liver, or bone precedes the diagnosis of CNS 
metastasis.10 
In this case, CNS metastasis was the first 
discovery so the patient underwent WBRT. 
At present, there is no evidence that early 
detection of brain metastases alters the chances 
of survival or the quality of life of patients 
with breast cancer, although no prospective 
studies have specifically addressed this issue. 
Conversely, although corticosteroids, WBRT, 
surgery and stereotactic radiosurgery (SRS) 
can provide excellent palliation of some 
symptoms, motor loss and other focal deficits 
are frequently not fully reversible. Therefore, 
it is possible that early detection may improve 
the quality of life by identifying patients for 
treatment before irreversible neurologic 
damage has occured. For many years, 
chemotherapy and endocrine therapy have 
not been considered as playing a role in the 
treatment of patients with brain metastases 
because of the presence of the blood-brain 
barrier (BBB). Most chemotherapy agents used 
in the treatment of breast cancer either do not 
cross an intact BBB, or are pumped out of the 
CNS by phosphoglycoprotein in the endothelial 
cells comprising the BBB. They may not reach 
sufficient therapeutic levels to treat CNS 
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metastases. The finding that chemotherapy 
and trastuzumab treatment are associated 
with improved survival even after adjusting 
for relevant variables in patients after the 
development of CNS metastases is interesting. 
The studies have proved the permeability of 
the blood–brain barrier in patients with brain 
metastases and in patients after WBRT. It has 
also been observed that systemic therapy 
carried out after WBRT prolongs survival due 
to the control of extracranial disease. Actually, 
after WBRT of brain metastases, the blood–
brain barrier is, in part, disrupted so that many 
chemotherapeutics and hormonal agents may 
reach a therapeutic level in tumors.11 
Trastuzumab in combination with 
chemotherapy significantly improves OS and 
disease-free survival in Her2-positive BC. 
The median overall survival (OS) for BCBM 
patients treated with whole brain radiotherapy 
(WBRT) alone is poor being of less than 6 
months. More recent analyses suggest that 
the prognosis of BCBM patients, especially 
those with Her2-positive BCBM is improving 
which is probably a result of better systemic 
treatment options leading to better control of 
the disease outside the central nervous system 
(CNS).12,13
This case suggests that appropriate 
treatment with whole brain radiotherapy 
followed by trastuzumab combined with 
chemotherapy remains the best option for 
giving a long, good quality life to patients who 
present with brain metastasis in luminal B 
Her2-positive stage IV breast cancer.   
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